Sign in

    Judah Grodin

    Research Analyst at UBS

    Judah Grodin is an Executive Director and Equity Research Analyst at UBS, specializing in the healthcare sector with a focus on the biotechnology and pharmaceuticals industries. He covers notable companies such as Biogen, Gilead Sciences, Amgen, and Vertex Pharmaceuticals, earning recognition for his detailed sector insight and investment recommendations. Grodin began his career after graduating from Brown University in 2008, previously holding research roles at Leerink Partners before joining UBS in 2017, where he has built a strong track record on platforms like TipRanks with a success rate exceeding 60% and above-market investment returns. He is FINRA registered, holding Series 7, 63, 86, and 87 licenses, and is regarded as a reliable specialist in biotech research and stock analysis.

    Judah Grodin's questions to FLUOR (FLR) leadership

    Judah Grodin's questions to FLUOR (FLR) leadership • Q1 2025

    Question

    Judah Grodin, on behalf of Steve Fisher, asked about the remaining project exposure in Mexico that could create future margin drag and inquired about the potential for cash collections from joint ventures during the year.

    Answer

    CFO John Regan and CEO James Breuer stated they feel good about the four major ongoing projects in Mexico, with most being in late stages, and do not expect further surprises. They clarified the recent reserve was for a project completed many years ago. Regarding JVs, Regan noted cash collection potential is likely lower than last year but is incorporated into the existing full-year cash flow guidance.

    Ask Fintool Equity Research AI